Aluminum Oxide Bryonia Alba Root Citrullus Colocyn
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Bryonia Alba Root Citrullus Colocyn
- Multi-Ingredient Homeopathic Preparation: No TxGNN Repurposing Prediction Available
Multi-Ingredient Homeopathic Preparation: No TxGNN Repurposing Prediction Available
One-Sentence Summary
This candidate is a nine-ingredient homeopathic mixture — including Bryonia Alba, Nux-Vomica, Sulfur, and potentially toxic heavy metal compounds such as Lead Acetate Anhydrous and Mercuric Chloride — with no recorded original indication and no US market authorization. The TxGNN model was unable to generate any repurposing prediction, as no DrugBank identifier could be resolved for this preparation, preventing knowledge-graph traversal. Without a prediction anchor or mapped indication, a standard repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN did not generate a prediction |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (prediction-only basis — and none generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No prediction was generated. The TxGNN pipeline requires a valid DrugBank ID to anchor the compound as a node in the knowledge graph. Because this preparation is a heterogeneous nine-ingredient mixture with no single resolvable DrugBank entry, the system returned no candidates. DrugBank did return one result during querying, but a compound-level identifier could not be confirmed.
The composition itself presents additional concerns independent of the pipeline failure. Three ingredients carry well-documented toxicity profiles in conventional doses: Lead Acetate Anhydrous (cumulative heavy metal neurotoxin, IARC Group 2A probable carcinogen), Mercuric Chloride (highly corrosive, causes acute renal failure and neurological damage), and Strychnos Nux-Vomica Seed (contains strychnine, a glycine receptor antagonist capable of causing fatal convulsions). While homeopathic preparations use extreme serial dilutions that may substantially reduce or eliminate pharmacological activity, the mixture as formulated cannot be characterized as a conventional pharmaceutical compound amenable to standard repurposing analysis.
Without a mechanistic anchor — no MOA data, no DrugBank ID, and no mapped original indication — there is no scientifically coherent basis to hypothesize a new therapeutic use through the TxGNN framework.
Clinical Trial Evidence
Currently no related clinical trials registered. TxGNN did not produce a predicted indication, so no evidence search was initiated.
Literature Evidence
Currently no related literature available at the compound level. Individual ingredients (e.g., Bryonia Alba, Lycopodium Clavatum) have independent ethnobotanical literature, but this falls outside the scope of the TxGNN repurposing pipeline.
Safety Considerations
This preparation contains ingredients with serious toxicity potential in non-homeopathic doses. The following is provided for awareness pending receipt of the actual formulation dossier (dilution potency, route of administration):
- Lead Acetate Anhydrous: Cumulative heavy metal poison causing nephrotoxicity, peripheral neuropathy, and encephalopathy. Probable human carcinogen (IARC Group 2A). No safe non-trivial exposure level recognized in conventional medicine.
- Mercuric Chloride: Severely corrosive. Causes acute tubular necrosis, gastrointestinal haemorrhage, and CNS damage. Prohibited or tightly restricted in pharmaceutical products in most jurisdictions.
- Strychnos Nux-Vomica Seed (strychnine): Competitive glycine antagonist. Lethal dose in humans is approximately 1–2 mg/kg; convulsions, opisthotonus, and respiratory arrest are the primary toxidrome.
- Lachesis Muta Venom: Haemotoxic and neurotoxic snake venom. Causes disseminated intravascular coagulation and local tissue necrosis in conventional exposure.
A complete safety review requires the homeopathic dilution potency (e.g., 6C, 30C, 200C) for each ingredient, which determines whether any pharmacologically active quantity is actually present.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN could not generate a repurposing prediction because no DrugBank ID was resolvable for this nine-ingredient homeopathic mixture, and the preparation contains substances — particularly lead, mercury, and strychnine precursors — whose safety characterization at the formulation level must be completed before any repurposing pathway is considered.
To proceed, the following is needed:
- Confirm the homeopathic dilution potency (potency level) for each of the nine ingredients, as this is the single most important factor determining actual risk
- Determine whether the intent is to evaluate the mixture as a whole, or to submit individual active components (e.g., Bryonia Alba, Lycopodium Clavatum) separately to TxGNN using their respective DrugBank IDs
- Obtain the full regulatory dossier (package insert, TFDA/FDA classification) and route of administration for this preparation
- Resolve the DrugBank identifier gap (one result was returned but not confirmed) before resubmitting to the pipeline
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.